Clinical Trials Logo

Clinical Trial Summary

This is a phase 1/2, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate safety, immunogenicity and efficacy of JHM03 for the treatment of moderate to severe glabellar lines in male and female subjects of Chinese origin. The purpose of this study was to observe efficacy and safety of JHM03 compared with placebo and BOTOX® in moderate to severe glabellar lines.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Moderate to Severe Glabellar Lines

NCT number NCT06199336
Study type Interventional
Source JHM BioPharma (Tonghua) Co. , Ltd.
Contact Danhua Lin
Phone 15811460241
Email danhua.lin@jhm-biopharma.com
Status Recruiting
Phase Phase 1/Phase 2
Start date January 19, 2024
Completion date January 24, 2025

See also
  Status Clinical Trial Phase
Completed NCT05743634 - A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines Phase 1/Phase 2
Completed NCT05463965 - A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines Phase 3
Completed NCT06151561 - Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines Phase 1
Completed NCT02353871 - Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines Phase 3
Completed NCT06354127 - DWP450 for Treating Moderate to Severe Glabellar Lines Phase 3
Completed NCT03970876 - Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects Phase 1/Phase 2